Tepmetko Alternatives Compared
| Tepmetko (tepotinib) | Nivolumab | Rybrevant (amivantamab) |
|
|---|
| Tepmetko (tepotinib) | Nivolumab | Rybrevant (amivantamab) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Non Small Cell Lung Cancer. Tepmetko may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Esophageal Carcinoma, Head and Neck Cancer, Colorectal Cancer, Hepatocellular Carcinoma, Gastric Cancer, Hodgkin's Lymphoma, Malignant Pleural Mesothelioma, Melanoma, Melanoma -... View more |
Prescription only
Prescribed for Non Small Cell Lung Cancer. Rybrevant may also be used for purposes not listed in this medication guide. |
||||||||||||||||
| More about Tepmetko (tepotinib) | More about Nivolumab | More about Rybrevant (amivantamab) | ||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||
|
Be the first to share your experience with this drug. |
Nivolumab has an average rating of 5.5 out of 10 from a total of 128 ratings on Drugs.com. 48% of reviewers reported a positive effect, while 45% reported a negative effect. |
Rybrevant has an average rating of 8.5 out of 10 from a total of 4 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||||||||||
| Drug Class | ||||||||||||||||||
| Side Effects | ||||||||||||||||||
| Generic Availability | ||||||||||||||||||
|
N/A |
N/A |
|||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
View all Tepmetko prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Rybrevant prices |
||||||||||||||||
| Dosage Forms Available | ||||||||||||||||||
|
N/A |
|
||||||||||||||||
| Brand Names | ||||||||||||||||||
|
N/A |
Opdivo |
N/A |
||||||||||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||
|
N/A |
640.8 hours |
271.2 hours |
||||||||||||||||
| CSA Schedule ** View glossary of terms | ||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | ||||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | ||||||||||||||||||
|
A total of 279 drugs are known to interact with Tepmetko:
|
A total of 402 drugs are known to interact with Nivolumab:
|
A total of 14 drugs are known to interact with Rybrevant:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||
| Disease Interactions | ||||||||||||||||||
| First Approval Date | ||||||||||||||||||
|
February 03, 2021 |
December 22, 2014 |
N/A |
||||||||||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| More Information | ||||||||||||||||||
| Patient resources | ||||||||||||||||||
| Professional Resources | ||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.